Heidi Overton's nomination to become the next FDA commissioner has been withdrawn by the White House prior to a Senate committee vote. Overton, who was nominated by President Donald Trump, faced criticism from supporters of Health and Human Services Secretary Robert F. Kennedy Jr. for her industry ties and from anti-abortion activists regarding her stance on the abortion pill mifepristone. HELP Chairman Bill Cassidy expressed concerns about her role in vaccine recommendations.
Key facts
- Heidi Overton's nomination for FDA commissioner was withdrawn by the White House.
- The Senate committee was scheduled to consider her nomination on November 18, 2026.
- Overton was nominated by President Donald Trump to replace acting Commissioner Kyle Diamantas.
- Critics included supporters of Robert F. Kennedy Jr. and anti-abortion activists.
- HELP Chairman Bill Cassidy expressed concerns about Overton's role in vaccine recommendations.
A short AI summary in our own words. The reporting belongs to Washington Examiner; we don't reproduce it.